Laura S Gold1, Ryan N Hansen2, Donald L Patrick3, Ashley Tabah4, Sonya L Heltshe5, Patrick A Flume6, Christopher H Goss7, Natalie E West8, Don B Sanders9, Donald R VanDevanter10, Larry Kessler3. 1. Department of Radiology, University of Washington, O1-140-6 UW Tower, 4333 Brooklyn Ave NE, Box 359558, Seattle, WA 98195-9558, United States. Electronic address: goldl@uw.edu. 2. School of Pharmacy, University of Washington, Seattle, WA, United States; Department of Health Services, University of Washington, Seattle, WA, United States. 3. Department of Health Services, University of Washington, Seattle, WA, United States. 4. School of Pharmacy, University of Washington, Seattle, WA, United States. 5. Department of Pediatrics, University of Washington, Seattle, WA, United States; Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, United States. 6. Departments of Medicine and Pediatrics, Medical University of South Carolina, Charleston, SC, United States. 7. Department of Pediatrics, University of Washington, Seattle, WA, United States; Department of Medicine, University of Washington, Seattle, WA, United States. 8. Department of Medicine, Johns Hopkins University, Baltimore, MD, United States. 9. Department of Pediatrics, Indiana University, Indianapolis, IN, United States. 10. Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
Abstract
BACKGROUND: The purpose of these analyses was to determine whether overall costs were reduced in cystic fibrosis (CF) patients experiencing pulmonary exacerbation (PEx) who received shorter versus longer durations of treatment. METHODS: Among people with CF experiencing PEx, we calculated 30-day inpatient, outpatient, emergency room, and medication costs and summed these to derive total costs in 2020 USD. Using the Kaplan-Meier sample average (KMSA) method, we calculated adjusted costs and differences in costs within two pairs of randomized groups: early robust responders (ERR) randomized to receive treatment for 10 days (ERR-10 days) or 14 days (ERR-14 days), and non-early robust responders (NERR) randomized to receive treatment for 14 days (NERR-14 days) or 21 days (NERR-21 days). RESULTS: Patients in the shorter treatment duration groups had shorter lengths of stay per hospitalization (mean ± standard deviation (SD) for ERR-10 days: 7.9 ± 3.0 days per hospitalization compared to 10.1 ± 4.2 days in ERR-14 days; for NERR-14 days: 8.7 ± 4.9 days per hospitalization compared to 9.6 ± 6.5 days in NERR-21 days). We found statistically significantly lower adjusted mean costs (95% confidence interval) among those who were randomized to receive shorter treatment durations (ERR-10 days: $60,800 ($59,150 - $62,430) vs $74,420 ($72,610 - $76,450) in ERR-14 days; NERR-14 days: $66,690 ($65,960-$67,400) versus $74,830 ($73,980-$75,650) in NERR-21 days). CONCLUSIONS: Tied with earlier evidence that shorter treatment duration was not associated with worse clinical outcomes, our analyses indicate that treating with shorter antimicrobial durations can reduce costs without diminishing clinical outcomes.
BACKGROUND: The purpose of these analyses was to determine whether overall costs were reduced in cystic fibrosis (CF) patients experiencing pulmonary exacerbation (PEx) who received shorter versus longer durations of treatment. METHODS: Among people with CF experiencing PEx, we calculated 30-day inpatient, outpatient, emergency room, and medication costs and summed these to derive total costs in 2020 USD. Using the Kaplan-Meier sample average (KMSA) method, we calculated adjusted costs and differences in costs within two pairs of randomized groups: early robust responders (ERR) randomized to receive treatment for 10 days (ERR-10 days) or 14 days (ERR-14 days), and non-early robust responders (NERR) randomized to receive treatment for 14 days (NERR-14 days) or 21 days (NERR-21 days). RESULTS: Patients in the shorter treatment duration groups had shorter lengths of stay per hospitalization (mean ± standard deviation (SD) for ERR-10 days: 7.9 ± 3.0 days per hospitalization compared to 10.1 ± 4.2 days in ERR-14 days; for NERR-14 days: 8.7 ± 4.9 days per hospitalization compared to 9.6 ± 6.5 days in NERR-21 days). We found statistically significantly lower adjusted mean costs (95% confidence interval) among those who were randomized to receive shorter treatment durations (ERR-10 days: $60,800 ($59,150 - $62,430) vs $74,420 ($72,610 - $76,450) in ERR-14 days; NERR-14 days: $66,690 ($65,960-$67,400) versus $74,830 ($73,980-$75,650) in NERR-21 days). CONCLUSIONS: Tied with earlier evidence that shorter treatment duration was not associated with worse clinical outcomes, our analyses indicate that treating with shorter antimicrobial durations can reduce costs without diminishing clinical outcomes.
Authors: Esi Morgan Dewitt; Chelsea A Grussemeyer; Joëlle Y Friedman; Michaela A Dinan; Li Lin; Kevin A Schulman; Shelby D Reed Journal: Value Health Date: 2012-01-27 Impact factor: 5.725
Authors: Eric W Christensen; Alicen Burns Spaulding; William F Pomputius; Steven P Grapentine Journal: J Pediatric Infect Dis Soc Date: 2019-05-11 Impact factor: 3.164
Authors: Jennifer L Taylor-Cousar; Anne Munck; Edward F McKone; Cornelis K van der Ent; Alexander Moeller; Christopher Simard; Linda T Wang; Edward P Ingenito; Charlotte McKee; Yimeng Lu; Julie Lekstrom-Himes; J Stuart Elborn Journal: N Engl J Med Date: 2017-11-03 Impact factor: 91.245
Authors: Bruce C Trapnell; Su Chen; Rupal Khurmi; Amit Bodhani; Mudra Kapoor; Mark Haupt Journal: Chron Respir Dis Date: 2020 Jan-Dec Impact factor: 2.444